American Society of Clinical Oncology

SHERPA: White

People

  1. Feldman
    Feldman
  2. Bosl
    Bosl
  3. Chaganti
    Chaganti
  4. Motzer
    Motzer
  5. Pandit-Taskar
    Pandit-Taskar
  6. Al-Ahmadie
    Al-Ahmadie
  7. Arcila
    Arcila
  8. Bains
    Bains
  9. Cha
    Cha
  10. Iyer
    Iyer

Groups

  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Sloan Kettering Institute Faculty (7)
  4. Solid Tumor Oncology Division (7)
  5. GSK Faculty (5)
  6. Biostatistics Service (4)
  7. Cell Biology Program Faculty (4)
  8. Epidemiology and Biostatistics (4)
  9. Survivorship Research (4)
  10. Molecular Imaging and Therapy Service (3)
Search Within
  1. "Sloan Kettering Institute Faculty"
  2. "Darren Feldman"
Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Department of Medicine (7)
  2. Genitourinary Oncology Service (7)
  3. Sloan Kettering Institute Faculty (7)
  4. Solid Tumor Oncology Division (7)
  5. GSK Faculty (5)
  6. Biostatistics Service (4)

More Groups

People
  1. Darren Feldman (7)
  2. George Bosl (4)
  3. Raju Chaganti (4)
  4. Victor Reuter (4)
  5. Neeta Pandit-Taskar (3)
  6. Robert Motzer (3)

More People

Years
  1. 2023 (1)
  2. 2022 (1)
  3. 2016 (1)
  4. 2015 (1)
  5. 2012 (1)
  6. 2009 (1)

More Years

Publications
  1. Journal of Clinical Oncology (7)

Results (7)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • STARLITE 2: Phase 2 study of nivolumab plus (177)lutetium-labeled anti–carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • STARLITE 2: Phase 2 study of nivolumab plus (177)Lutetium-labeled anti-carbonic anhydrase IX (CAIX) monoclonal antibody girentuximab ((177)Lu-girentuximab) in patients (pts) with advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Feldman, D. R.; Motzer, R. J.; Knezevic, A.; Lee, C. H.; Voss, M. H.; Lyashchenko, S. K.; Park, H.; Larson, S. M.; Pandit-Taskar, N.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Genetic determinants of cisplatin resistance in patients with advanced germ cell tumors
    Journal Article

    Bagrodia, A.; Lee, B. H.; Lee, W.; Cha, E. K.; Sfakianos, J. P.; Iyer, G.; Pietzak, E. J.; Gao, S. P.; Zabor, E. C.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Association of genomic alterations with cisplatin resistance (cisR) in advanced germ cell tumors (aGCT)
    Meeting Abstract

    Feldman, D. R.; Bagrodia, A.; Lee, B.; Lee, W.; Al-Ahmadie, H.; Cha, E. K.; Sfakianos, J.; Iyer, G.; Zabor, E. C.; Ostrovnaya, I.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • (124)I-cG250 PET scan for early detection of response to sunitinib in patients (Pts) with metastatic clear cell renal cell carcinoma (MccRCC)
    Meeting Abstract

    Larson, S. M.; Motzer, R. J.; Pandit-Taskar, N.; Bartz, R.; Feldman, D. R.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Identification and validation of a gene expression signature that predicts outcome in adult men with germ cell tumors
    Journal Article

    Korkola, J. E.; Houldsworth, J.; Feldman, D. R.; Olshen, A. B.; Qin, L. X.; Patil, S.; Reuter, V. E.; Bosl, G. J.; Chaganti, R. S. K.
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save
  • Outcome prediction in adult male germ cell tumor patients through expression profiling
    Meeting Abstract

    Korkola, J.; Houldsworth, J.; Feldman, D. R.; Olshen, A. B.; Qin, L.; Patil, S.; Reuter, V. E.; Bosl, G. J.; Chaganti, R. S.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save